COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,026 Articles (22,627 medRxiv, 8,399 bioRxiv)

Most recent first Previous |  Page 133: Articles 1321-1330  | Next

Changes in population immunity to omicron SARS-CoV-2 variants and selected Sarbecoviruses from 2020 to 2023 in urban Colombo, Sri Lanka
Bary, F., Karunananda, M. V., Jeewandara, C., Danasekara, S., Guruge, D., Rizan, R., Aberathna, I. S., Ranasinghe, T., Kuruppu, H., Jayamali, J., Perera, L., Chathurangika, H., Gunaratne, A., Dasanthi, N., Ranatunga, C., Ishara, A. W. S., Yatiwelle, S., Wijayamuni, R., Tang, T. K., Townsend, A., Ogg, G. S., Malavige, G. N.
10.1101/2024.10.03.24314822 — Posted: 2024-10-04
Measurement of doctor wellbeing prior to the Covid pandemic: a methodological systematic review
Simons, G., Opalinski, D., Jenkins, J., Boxley, E., Baldwin, D.
10.1101/2024.10.03.24314759 — Posted: 2024-10-04
Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A Systematic Literature Review
Rudolph, A. E., Al Akoury, N., Bogdanenko, N., Markus, K., Whittle, I., Wright, O., Haridy, H., Spinardi, J. R., McLaughlin, J. M., Kyaw, M. H.
10.1101/2024.10.02.24314603 — Posted: 2024-10-04
Comparative Analysis of Lipid Nanoparticles in Pfizer-BioNTech and Moderna COVID-19 Vaccines: Insights from Molecular Dynamics Simulations
Biswal, M. R., Roy, S., Singh, J. K.
10.1101/2024.10.04.616619 — Posted: 2024-10-04
Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC
Arora, P., Happle, C., Kempf, A., Nehlmeier, I., Stankov, M. V., Dopfer-Jablonka, A., Behrens, G. M. N., Poehlmann, S., Hoffmann, M.
10.1101/2024.10.04.616448 — Posted: 2024-10-04
Computational design of developable therapeutic antibodies: efficient traversal of binder landscapes and rescue of escape mutations
Dreyer, F. A., Schneider, C., Kovaltsuk, A., Cutting, D., Byrne, M. J., Nissley, D. A., Wahome, N., Kenlay, H., Marks, C., Errington, D., Gildea, R. J., Damerell, D., Tizei, P., Bunjobpol, W., Darby, J. F., Drulyte, I., Hurdiss, D. L., Surade, S., Pires, D. E. V., Deane, C. M.
10.1101/2024.10.03.616038 — Posted: 2024-10-04
Longitudinal analysis of B- and T-cell responses to SARS-CoV-2 recombinant S-protein vaccine S-268019-b in phase 1/2 priming and booster study
Fujitani, M., Lu, X., Shinnakasu, R., Inoue, T., Kidani, Y., Seki, N. M., Ishida, S., Mitsuki, S., Ishihara, T., Aoki, M., Suzuki, A., Takahashi, K., Takayama, M., Ota, T., Iwata, S., Yokokawa Shibata, R., Sonoyama, T., Ariyasu, M., Kitano, A., Terooatea, T., Kelly Villa, J., Yamashita, K., Yamasaki, S., Kurosaki, T., Omoto, S.
10.1101/2024.10.01.24314659 — Posted: 2024-10-03
Association between SARS-CoV-2 and Stroke: Perspectives from a metaumbrella-review.
Baldo de Souza, A. M. L., de Araujo, E. F., Pereira, A. C., Junior, N. C., Raimundo, A. C., Meneghim, M. d. C.
10.1101/2024.10.01.24314742 — Posted: 2024-10-03
Delayed viral clearance and altered inflammatory responses resulted in increased severity of SARS-CoV-2 infection in aged mice.
Lacasse, E., Dubuc, I., Gudimard, L., Dos Santos Pereira Andrade, A. C., Gravel, A., Greffard, K., Chamberland, A., Oger, C., Galano, J.-M., Durand, T., Philipe, E., Blanchet, M.-R., Bilodeau, J.-F., Flamand, L.
10.1101/2024.10.03.616431 — Posted: 2024-10-03
Serum proteomics reveals high-affinity and convergent antibodies by tracking SARS-CoV2 hybrid immunity to emerging variants of concern
Patel, A., Lima, T., Carson, R., Huang, Q., Bonissone, S. R., Castellana, N.
10.1101/2024.10.02.616394 — Posted: 2024-10-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).